DGAP-News: ENDRA Life Sciences to Showcase TAEUS(R) Technology at EASL International Liver Congress 2020
ANN ARBOR, MI / ACCESSWIRE / August 27, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS(R)), is exhibiting at The Digital International Liver Congress (ILC), hosted by the European Association for the Study of the Liver (EASL), Aug. 27-29, 2020.
DGAP-News: ENDRA Life Sciences Inc. / Key word(s): Miscellaneous ENDRA Life Sciences to Showcase TAEUS(R) Technology at EASL International Liver Congress 2020 27.08.2020 / 15:00 The issuer is solely responsible for the content of this announcement. ENDRA Life Sciences to Showcase TAEUS(R) Technology at EASL International Liver Congress 2020 ANN ARBOR, MI / ACCESSWIRE / August 27, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS(R)), is exhibiting at The Digital International Liver Congress (ILC), hosted by the European Association for the Study of the Liver (EASL), Aug. 27-29, 2020. "Clinical conferences and trade shows continue to be a key component of our brand awareness and commercialization strategies, and none more so than EASL," said ENDRA's Chief Commercial Officer, Renaud Maloberti. "This will be our first virtual conference since the onset of the global pandemic, and we've responded to this new reality with a virtual booth, which we're excited to reveal later this week. Our new virtual, interactive booth enables us to provide EASL attendees with a memorable experience of our innovative TAEUS solution and a unique introduction to our knowledgeable ENDRA team." ENDRA's TAEUS Fatty Liver Imaging Probe (FLIP) System is a practical, non-invasive way to assess liver fat at the point of care. Following TAEUS' receipt of the CE Mark earlier this year, ENDRA has focused on executing key components of its European commercialization plan, including establishing clinical evaluation sites that use TAEUS to measure and monitor liver fat. Simultaneously, ENDRA has also submitted a 510(k) to the U.S. FDA for the TAEUS FLIP, which is currently under review. ILC, which this year is "hosted" in London, provides another opportunity for ENDRA to drive awareness of TAEUS in this crucial market. The event attracts thousands of clinicians and scientists in hepatology, gastroenterology, pathology, radiology, imaging, and more, from all over the world to network, share data, present findings, and discuss the hottest topics and trends around liver disease. Following the conference, ENDRA's virtual trade show booth will be accessible on the company's website or directly at www.endrataeus.com. Hepatologists, gastroenterologists, radiologists, and other clinicians can get an immersive, highly-engaging look at TAEUS and experience it for themselves on their own time -- independent of conference dates. About ENDRA Life Sciences Inc. Forward-Looking Statements Company Contact: Media Relations Contact: Investor Relations Contact: SOURCE: ENDRA Life Sciences Inc.
27.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
1123833 27.08.2020